CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240
Last updated 2026-05-06
Summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Conditions
- Diabetic Macular Edema
- DME
- Diabetic Macular Edema (DME)
Interventions
- DRUG
-
EYP-1901
Intravitreal Injection
- DRUG
-
Aflibercept (2.0 mg)
Intravitreal Injection
Sponsors & Collaborators
-
EyePoint Pharmaceuticals, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-09
- Primary Completion
- 2027-10-31
- Completion
- 2028-10-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
NCT04603937 ·Status: TERMINATED ·Phase: PHASE3
-
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
NCT04429503 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
NCT00789477 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema
NCT03126786 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT03481660 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement
NCT01783886 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema
NCT02633852 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT03917472 ·Status: COMPLETED ·Phase: PHASE3
-
Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.
NCT02581995 ·Status: COMPLETED ·Phase: PHASE4
-
Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece
NCT05683912 ·Status: COMPLETED
-
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
NCT06422507 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema
NCT00367133 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema
NCT05324774 ·Status: UNKNOWN ·Phase: PHASE3
-
A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
NCT03397264 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Avoralstat In Participants With Diabetic Macular Edema
NCT07228559 ·Status: TERMINATED ·Phase: PHASE1
-
Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept
NCT05610488 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
NCT04288232 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
NCT01363440 ·Status: COMPLETED ·Phase: PHASE3
-
The Endurance 1 Trial
NCT02297204 ·Status: COMPLETED ·Phase: PHASE4
-
Non-Responsive Diabetic Macular Edema and Spironolactone
NCT04853355 ·Status: WITHDRAWN ·Phase: PHASE4
-
Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial
NCT02299336 ·Status: COMPLETED ·Phase: PHASE4
-
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
NCT07118670 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema
NCT04014556 ·Status: COMPLETED ·Phase: NA
-
Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa
NCT02554747 ·Status: COMPLETED ·Phase: NA